Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DBH | P09172 | 17/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10621834 | 0.81 | DBH (1.00) | DBHALDH1A1CYP1A2POLBCYP3A4 | |
| SCHEMBL10621922 | 0.78 | DBH (1.00) | DBHALDH1A1CYP1A2POLBCYP3A4 | |
| SCHEMBL10624621 | 0.71 | DBH (1.00) | DBHALDH1A1CYP1A2POLBCYP3A4 | |
| SCHEMBL3179236 | 0.71 | DBH (0.55) | DBHALDH1A1CYP1A2POLBCYP3A4 | |
| SCHEMBL9371273 | 0.69 | DBH (0.60) | DBHALDH1A1CYP1A2POLBCYP3A4 | |
| SCHEMBL11565383 | 0.66 | — | — | |
| Hydrochloric Acid SCHEMBL10532035 | 0.65 | DBH (0.47) | DBHALDH1A1 | |
| SCHEMBL9369333 | 0.62 | DBH (0.56) | DBHALDH1A1CYP1A2POLBCYP3A4 | |
| SCHEMBL9375216 | 0.62 | DBH (0.56) | DBHALDH1A1CYP1A2POLBCYP3A4 | |
| SCHEMBL10448529 | 0.62 | DBH (0.47) | DBHALDH1A1CYP1A2POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054403-A1 | Treatment of Post-Traumatic Stress Disorder | SYNOSIA THERAPEUTICS (US) | 2009-02-26 | — | — | US | disclosed |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | disclosed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | disclosed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | disclosed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | DBH 4/4885ALDH1A1 100/4885CYP1A2 1710/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | DBH 2/4885ALDH1A1 114/4885CYP1A2 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.